Douglas Fambrough

Douglas Fambrough, listed as chief executive, appears in our data through filings on Dicerna Pharmaceuticals Inc shares, published by SEC (Form 4). We count 14 filings; the first trade dates from 14 November 2016 and the latest from 28 December 2021.

The open-market side counts 4 purchases for €359k alongside 4 sales for €3.2M. The net balance comes to €2.9M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 1 share grant and 4 option exercises. In 2021 alone, the filings show 1 purchase and no sales.

The median purchase comes to €76k. Of 4 purchases, 1 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

On 29 December 2021 came the latest disclosure, a transaction for €7.8M in Dicerna Pharmaceuticals Inc. The most recent open-market purchase was published on 10 August 2021, 1,901 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.